297 related articles for article (PubMed ID: 27391263)
1. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS; Ferraldeschi R; Krupa R; Landers M; Graf R; Louw J; Jendrisak A; Bales N; Marrinucci D; Zafeiriou Z; Flohr P; Sideris S; Crespo M; Figueiredo I; Mateo J; de Bono JS; Dittamore R; Tomlins SA; Attard G
BJU Int; 2017 Nov; 120(5B):E30-E44. PubMed ID: 27539393
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
4. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
5. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
6. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
[TBL] [Abstract][Full Text] [Related]
7. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
8. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
Sieuwerts AM; Onstenk W; Kraan J; Beaufort CM; Van M; De Laere B; Dirix LY; Hamberg P; Beeker A; Meulenbeld HJ; Creemers GJ; van Weerden WM; Jenster GW; Nieuweboer AJM; Mathijssen RHJ; de Wit R; Martens JWM; Sleijfer S
Mol Oncol; 2019 Aug; 13(8):1795-1807. PubMed ID: 31180178
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
[TBL] [Abstract][Full Text] [Related]
10. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
Crespo M; van Dalum G; Ferraldeschi R; Zafeiriou Z; Sideris S; Lorente D; Bianchini D; Rodrigues DN; Riisnaes R; Miranda S; Figueiredo I; Flohr P; Nowakowska K; de Bono JS; Terstappen LW; Attard G
Br J Cancer; 2015 Mar; 112(7):1166-74. PubMed ID: 25719830
[TBL] [Abstract][Full Text] [Related]
13. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Onstenk W; Sieuwerts AM; Kraan J; Van M; Nieuweboer AJ; Mathijssen RH; Hamberg P; Meulenbeld HJ; De Laere B; Dirix LY; van Soest RJ; Lolkema MP; Martens JW; van Weerden WM; Jenster GW; Foekens JA; de Wit R; Sleijfer S
Eur Urol; 2015 Dec; 68(6):939-45. PubMed ID: 26188394
[TBL] [Abstract][Full Text] [Related]
17. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
18. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
19. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.
Friedlander TW; Ngo VT; Dong H; Premasekharan G; Weinberg V; Doty S; Zhao Q; Gilbert EG; Ryan CJ; Chen WT; Paris PL
Int J Cancer; 2014 May; 134(10):2284-93. PubMed ID: 24166007
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
